دورية أكاديمية

Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection Into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One-Year Follow-Up of a Randomized Pilot Study.

التفاصيل البيبلوغرافية
العنوان: Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection Into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One-Year Follow-Up of a Randomized Pilot Study.
المؤلفون: Pokushalov, Evgeny, Kozlov, Boris, Romanov, Alexander, Strelnikov, Artem, Bayramova, Sevda, Sergeevichev, David, Bogachev-Prokophiev, Alexander, Zheleznev, Sergey, Shipulin, Vladimir, Lomivorotov, Vladimir V., Karaskov, Alexander, Po, Sunny S., Steinberg, Jonathan S.
المصدر: Circulation: Arrhythmia & Electrophysiology; Dec2015, Vol. 8 Issue 6, p1334-1341, 8p
مصطلحات موضوعية: ATRIAL fibrillation diagnosis, CORONARY heart disease surgery, CORONARY disease, ADIPOSE tissues, ATRIAL fibrillation, BOTULINUM toxin, COMPARATIVE studies, CORONARY artery bypass, HEART beat, INJECTIONS, LONGITUDINAL method, RESEARCH methodology, INTRAOPERATIVE care, MEDICAL cooperation, MYOCARDIAL depressants, RESEARCH, TIME, DISEASE relapse, PILOT projects, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, BLIND experiment, DIAGNOSIS
مستخلص: Background: Animal models suggest that the neurotransmitter inhibitor, botulinum toxin, when injected into the epicardial fat pads can suppress atrial fibrillation inducibility. The aim of this prospective randomized double-blind study was to compare the efficacy and safety of botulinum toxin injection into epicardial fat pads for preventing atrial tachyarrhythmias.Methods and Results: Patients with history of paroxysmal atrial fibrillation and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin, Merz, Germany; 50 U/1 mL at each fat pad; n=30) or placebo (0.9% normal saline, 1 mL at each fat pad; n=30) injection into epicardial fat pads during surgery. Patients were followed for 1 year to assess maintenance of sinus rhythm using an implantable loop recorder. All patients in both groups had successful epicardial fat pad injections without complications. The incidence of early postoperative atrial fibrillation within 30 days after coronary artery bypass graft was 2 of 30 patients (7%) in the botulinum toxin group and 9 of 30 patients (30%) in the placebo group (P=0.024). Between 30 days and up to the 12-month follow-up examination, 7 of the 30 patients in the placebo group (27%) and none of the 30 patients in the botulinum toxin group (0%) had recurrent atrial fibrillation (P=0.002). There were no complications observed during the 1-year follow-up.Conclusions: Botulinum toxin injection into epicardial fat pads during coronary artery bypass graft provided substantial atrial tachyarrhythmia suppression both early as well as during 1-year follow-up, without any serious adverse events.Clinical Trial Registration: URL: http://www.clinicaltrials.govTest. Unique identifier: NCT01842529. [ABSTRACT FROM AUTHOR]
Copyright of Circulation: Arrhythmia & Electrophysiology is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Supplemental Index
الوصف
تدمد:19413149
DOI:10.1161/CIRCEP.115.003199